ScripArcus Biosciences put a positive spin on Gilead Sciences’ decision not to opt in to further development of the HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma (ccRCC) on 18 February, no
ScripIn its latest effort to identify drugs with price increases that had the biggest impact on US health care spending, the Institute for Clinical and Economic Review (ICER) included Merck & Co.’s Key
ScripArcus may be finding a new therapeutic direction for its cancer ambitions with its HIF-2a inhibitor casdatifan, reporting data from a Phase I/Ib study on 24 October that indicate the candidate may be
Generics BulletinCabometyx (cabozantinib) originator Exelixis proclaimed that MSN Laboratories will be unable to launch its proposed US generic version of the blockbuster tyrosine kinase inhibitor for more than five y